Combined Angiography - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The combined angiography market size is expected to increase from USD 10.61 billion in 2025 to USD 11.22 billion in 2026 and reach USD 14.92 billion by 2031, growing at a CAGR of 5.85% over 2026-2031. This report is segmented by Product Type (Combined Angio-CT Systems and More), by Technology (Digital Subtraction Angiography (DSA) and More), by Application (Cardiovascular Intervention and More), by Procedure (Coronary Angiography and Percutaneous Coronary Intervention and More), by End User (Hospitals and More), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Combined Angiography Market Trends and Insights

Rising Cardiovascular, Neurovascular, and Peripheral Intervention Volumes

The combined angiography market benefits as procedure volumes rise across cardiovascular, neurovascular, and peripheral care. Germany's neurovascular networks performed more than 4,400 mechanical thrombectomies annually as of 2023 data, which was 82% above the 2017 to 2019 baseline. More secondary referral hospitals are gaining thrombectomy capability, which broadens demand beyond a small number of academic centers. Combined Angio-CT suites allow CT acquisition without moving the patient between rooms. This can reduce handoff risk during time-sensitive stroke and trauma pathways. At MD Anderson, 69% of transarterial chemoembolization and radioembolization activity shifted toward hybrid Angio-CT rooms after those rooms became available.

Shift Toward Hybrid Operating Rooms and Minimally Invasive Treatment

Hybrid operating rooms are expanding within the combined angiography market because they bring surgery and image-guided treatment into one setting. A high-volume center reported in-hospital mortality of 100% for transcatheter aortic valve replacement surgical bailout in conventional catheterization laboratories, compared with 33.3% in hybrid operating rooms. The difference reflected faster access to definitive surgical treatment. This clinical evidence affects how health systems assess the cost and risk of constructing hybrid rooms. AP-HP Henri Mondor inaugurated an interventional and ambulatory center with an Angio-CT suite in July 2026, showing continued public-hospital investment in this care model.

High Capital Cost and Room-Construction Complexity

The combined angiography market faces a significant adoption barrier, as a complete suite requires more than an imaging system. Projects require radiation shielding, ceiling systems, power infrastructure, room redesign, and specialized maintenance support. These requirements place combined systems within multi-year hospital capital expenditure plans. Public healthcare systems in the Middle East, South America, and Southeast Asia may experience longer tender cycles, approval backlogs, and foreign exchange constraints for USD-denominated equipment. Consequently, high clinical need does not always translate into installed capacity at the same pace. Although modular upgrades can reduce the initial purchase barrier, their lifecycle costs may remain close to those of a purpose-built room.

Other drivers and restraints analyzed in the detailed report include:

• Multimodality Image Fusion and Intra-Procedural Decision Support
• Aging Population and Chronic Disease Burden
• Radiation Dose, Contrast Exposure, and Procedure-Safety Concerns

Segment Analysis

Combined Angio-CT Systems held 46.18% of the combined angiography market share in 2025. Their position reflects the established need for CT-quality anatomy and fluoroscopy-guided treatment in the same room. This configuration supports interventional oncology, cardiovascular procedures, and complex endovascular repair. It also reduces the need to reposition a patient between the CT and angiography rooms. Canon Medical presented its Alphenix 4D CT at CIRSE 2025 with a 16-cm wide-area detector, a 0.24-second rotation time, and a high-definition flat-panel angiography C-arm. The platform illustrates how product development is combining CT and angiography functions within a single procedural environment.

Combined Angio-MR Systems serve procedures that need stronger soft-tissue contrast, especially cerebrovascular interventions. Combined Angio-CT-MR Systems are the fastest-growing product group, with an 8.5% CAGR through 2031. These systems can combine CT support for vascular and bone detail with MRI soft-tissue visualization. They suit centers focused on advanced interventional neurology and structural heart disease. Other hybrid angiography systems include mobile biplane systems and portable C-arms with cone-beam CT additions. These alternatives offer hospitals a route to hybrid capability when room-construction budgets are limited. The combined angiography market is therefore expected to move toward more complex multi-modality configurations as integrated procedural rooms become more common.

Digital Subtraction Angiography held 52.26% of technology revenue in 2025. It remains central to fluoroscopy-guided cardiovascular, neurovascular, and peripheral intervention. Long-standing training, clinical protocols, and a comparatively lower capital requirement support its installed base. Its role is being extended through image-processing tools rather than being rapidly replaced. A multicenter study reported that the SAVE-Net deep-learning frame synthesis approach reduced radiation dose by as much as 85.71% while maintaining real-time inference at 0.04 seconds per frame. These capabilities help preserve DSA's role in navigation and live decision-making.

3D Angiography is forecast to grow at an 8.9% CAGR through 2031, the fastest rate within the technology categories. Cone-beam CT reconstruction and AI-supported visualization give clinicians greater anatomical context than conventional 2D acquisition. The technology is relevant in brain arteriovenous malformation embolization, aneurysm coiling, and transcatheter aortic valve implantation assessment. A 2026 review found that 4D-DSA had diagnostic performance that was equivalent or superior to traditional DSA for brain arteriovenous malformation angioarchitecture. The review also found that 4D-DSA could show arterial aneurysms and shunt zones that conventional approaches may miss. 2D Angiography continues to serve hospitals that require a more accessible entry point to angiographic imaging.

Complete Report Scope:

• By Product Type
  • Combined Angio-CT Systems
  • Combined Angio-MR Systems
  • Combined Angio-CT-MR Systems
  • Other Hybrid Angiography Systems
• By Technology
  • Digital Subtraction Angiography (DSA)
  • 2D Angiography
  • 3D Angiography
  • Others (3D Rotational Angiography, 4D Angiography, etc.)
• By Application
  • Cardiovascular Intervention
  • Neurovascular Intervention
  • Peripheral Vascular Intervention
  • Interventional Oncology
  • Interventional Radiology
  • Others (Trauma, Structural Heart Intervention, etc.)
• By Procedure
  • Coronary Angiography and Percutaneous Coronary Intervention
  • Stroke Thrombectomy and Cerebral Angiography
  • Aneurysm Embolization and Flow-Diverter Procedures
  • Peripheral Angioplasty and Stenting
  • Transarterial Chemoembolization
  • Others (Ablation and Embolization Combinations, Transcatheter Valve Procedures, etc.)
• Market Size by End User
  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Specialized Cath Labs
  • Hybrid Operating Rooms
  • Academic and Research Centers
• Market Size by Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.11% of global revenue in 2025, the largest regional combined angiography market share. The United States supports this position through quaternary medical centers, reimbursement for complex structural heart and neurovascular procedures, and clinician adoption of AI-supported imaging. Siemens Healthineers received U.S. FDA clearance in May 2026 for 6 Artis interventional systems with the Optiq AI imaging chain. GE HealthCare received U.S. FDA 510(k) clearance for CleaRecon DL in May 2025. These introductions maintain the region's role in the adoption of advanced combined suites. Canadian transcatheter aortic valve replacement programs used hybrid operating rooms to improve efficiency while maintaining low adverse-event rates between 2019 and 2024. Mexico offers a developing opportunity through private investment at premium referral centers.

Europe is a major regional market, led by Germany, France, and the United Kingdom. Germany had 10.1 catheterization laboratories per million people and a certified neurovascular network that performed more than 4,400 mechanical thrombectomies annually. Its 2026 Hybrid-DRG framework covers 69 procedures and supports sector-neutral reimbursement for interventional cardiology and peripheral vascular care. This framework supports investment in combined suites for outpatient as well as inpatient use. France is adding capacity through AP-HP Henri Mondor's Angio-CT center, which opened in July 2026. Italy, Spain, and Nordic countries add demand through hospital modernization programs.

Asia-Pacific is forecast to grow at an 8.8% CAGR through 2031, the fastest regional rate in the combined angiography market. China, Japan, India, South Korea, and Australia are the principal demand centers. China is replacing older imaging equipment while adding capacity in urban and rural hospitals. Domestic vendors compete more actively in mid-tier tenders, while imported systems remain important at the premium end. Japan's aging population supports cardiovascular and neurovascular procedure activity. India's private hospital chains are increasing cardiac and neurological capacity. South Korea combines a dense tertiary hospital network with investment in medical-device manufacturing. The Middle East and Africa are led by premium-system procurement for GCC referral hospitals. South America is led by Brazil, where private health-plan coverage for structural heart procedures supports interventional cardiology adoption.

List of Companies Covered in this Report:

• Abbott Laboratories
• Agfa-Gevaert
• AngioDynamics
• B. Braun
• Boston Scientific
• Canon
• Cardinal Health
• FUJIFILM
• GE HealthCare Technologies Inc.
• Hologic
• Medtronic
• Mindray
• Neusoft
• Nevada technologies Inc.
• Philips Azurion
• Shimadzu
• Siemens Healthineers
• Terumo
• United Imaging Healthcare Co., Ltd.
• Ziehm Imaging

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support